We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AbCellera Biologics Inc. (ABCL - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AbCellera Biologics Inc. is one of 971 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABCL's full-year earnings has moved 8.3% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ABCL has moved about 66.2% on a year-to-date basis. At the same time, Medical stocks have lost an average of 2.7%. This means that AbCellera Biologics Inc. is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Astrazeneca (AZN - Free Report) . The stock has returned 13.1% year-to-date.
Over the past three months, Astrazeneca's consensus EPS estimate for the current year has increased 2.1%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 482 individual stocks and currently sits at #78 in the Zacks Industry Rank. On average, stocks in this group have gained 3.2% this year, meaning that ABCL is performing better in terms of year-to-date returns. Astrazeneca is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to AbCellera Biologics Inc. and Astrazeneca as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AbCellera Biologics Inc. (ABCL - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AbCellera Biologics Inc. is one of 971 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. AbCellera Biologics Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABCL's full-year earnings has moved 8.3% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ABCL has moved about 66.2% on a year-to-date basis. At the same time, Medical stocks have lost an average of 2.7%. This means that AbCellera Biologics Inc. is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Astrazeneca (AZN - Free Report) . The stock has returned 13.1% year-to-date.
Over the past three months, Astrazeneca's consensus EPS estimate for the current year has increased 2.1%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, AbCellera Biologics Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 482 individual stocks and currently sits at #78 in the Zacks Industry Rank. On average, stocks in this group have gained 3.2% this year, meaning that ABCL is performing better in terms of year-to-date returns. Astrazeneca is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to AbCellera Biologics Inc. and Astrazeneca as they could maintain their solid performance.